Nice compilation. But two points you don't mention. Potential Annual Revenues and Valuations are worthless as long as you have NOTHING finished, no product. Comparing BMSN with companies on the Nasdaq which have real products and revenues is like comparing apples with horse droppings. Even if it's only for valuation purposes.
BTW How do you know that we are so close to FDA approval? Or is it pure assumption and wishful thinking? Instead of approval it looks like more questions and further delays imo.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.